Does the rapid acceptance of ACOSOG Z0011 compromise selection of systemic therapy?

Annals of Surgical Oncology

Volumn 19, Issue 12, 2012, Pages 3643-3645

  Cody III, Hiram S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

BREAST CANCER; CANCER GRADING; CANCER SIZE; CANCER SURVIVAL; EDITORIAL; HUMAN; LYMPH NODE DISSECTION; OVERALL SURVIVAL; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; TREATMENT PLANNING; TRIPLE NEGATIVE BREAST CANCER; UNITED STATES;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DECISION MAKING; FEMALE; HUMANS; LYMPH NODE EXCISION; SENTINEL LYMPH NODE BIOPSY;

EID: 84868145566     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2508-y     Document Type: Editorial

References (16)

1. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma. Cancer. 2006;106:4-16. (Pubitemid 43033320)
2. Kell MR, Burke JP, Barry M, Morrow M. Outcome of axillary staging in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2010;120:441-7.
3. Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for nodepositive breast cancer. J Clin Oncol. 2009;27:2946-53.
4. Giuliano AE, McCall LM, Beitsch PD, Whitworth PW, Morrow M, Blumencranz PW, et al. ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node. J Clin Oncol (Meeting Abstracts). 2010;28:CRA506.
5. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305: 569-75.
6. Montemurro F, Maggiorotto F, Valabrega G, Kubatzki F, Rossi V, Magistris A, et al. Omission of axillary dissection after a positive sentinel node dissection may influence adjuvant chemotherapy indications in operable breast cancer patients. Ann Surg Oncol. doi:10.1245/s10434-012-2505-1.
7. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736-47.
8. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Version 1.2012. 2012. Accessed June 7, 2012.
9. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-717.
10. Early Breast Cancer Trialists' Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432-44.
11. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426-33.
12. Straver ME, Meijnen P, van TG, van de Velde CJ, Mansel RE, Bogaerts J, et al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol. 2010;28:731-7.
13. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. New Engl J Med. 2004;351:2817-26. (Pubitemid 40051905)
14. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726-34. (Pubitemid 46622311)
15. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with nodepositive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55-65.
16. Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006;7:347-50. (Pubitemid 44717771)